Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

ABSTRACT: This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.

DISEASE(S): Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma,Carcinoma, Non-small-cell Lung

PROVIDER: 2191063 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

RNAseq of organ-cultured human hair follicles exposed to MEKi (Cobimetinib)

Project description:EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of hair follicle immune privilege and differential modulation of IL-33 and IL-37 expression. Our findings suggest that successful future management of EGFRi/MEKi-induced folliculitis requires restoration of hair follicle immune privilege. In this RNAseq organ-cultured human hair follicles were directly exposed to MEKi (Cobimetinib) or the control DMSO (n=5 patients (6-8 hair follicles per patient)).

2024-07-19 | E-MTAB-13454 | biostudies-arrayexpress

ATAC-seq of MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We measured chromatin accessibility using ATAC-sequencing for MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246359 | GEO

RNA-seq of MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We measured gene expression using RNA-sequencing for MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246362 | GEO

Effect of treating DLD1 organoids with either single agent MEK (cobimetinib) inhibition or APC restoration on chromatin accessibility.

Project description:We show that single agent treatment with either cobimetinib or APC restoration, results in cell plasticity.

2026-04-05 | GSE301561 | GEO

RNAseq analysis of GL261 GDC and mNS GSC transcriptome

Project description:We compare the gene expression profile between GL261 glioma differentiated cells (GDC) and mNS Neurospheres glioma stem like cells (GSC).

2017-02-03 | GSE94239 | GEO

MCF-7 RPMI ERa and FOXA1 ChIP-seq in GDC-9545 and GNE-858

Project description:We performed ChIPseq for ER, FOXA1 and H3K27ac on MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246361 | GEO

ChIP-seq of GATA3 in MCF-7 cells treated with GDC-9545 and GNE-858

Project description:We performed ChIPseq for GATA3 on MCF-7 cells treated with vehicle (DMSO), GDC-9545 or GNE-858. GNE-858 is a non-ER degrader (SERM) from the same chemical series as GDC-9545.

2026-03-01 | GSE246360 | GEO

Drug repurposing strategy reveals Cobimetinib as a promising disease-modifying drug for Osteoarthritis

Project description:Osteoarthritis (OA) is a common disabling disease for which no effective pharmacological therapy exists. The progression of osteoarthritis is characterized by the loss of homeostasis in the cartilage. Since in the early stages of the disease, a phenotypic switch is seen in which articular chondrocytes become hypertrophic and promote degradation of the cartilage extracellular matrix, targeting this phenomenon might be the key to developing a disease-modifying osteoarthritis drug (DMOAD). In this study, the signature reversing principle combined with a drug repurposing strategy was used to accelerate the identiﬁcation and validation of potential DMOADs. Starting from single-cell transcriptomic analysis of patient-derived cartilage, we identified 6 drugs predicted to reduce chondrocyte hypertrophy. Subsequent in vitro evaluation in human chondrocytes and cartilage explants demonstrated that Cobimetinib, a MEK1/2 inhibitor, reduced chondrocyte hypertrophy-related and catabolic gene expression, such as SPP1, COL10A1, MMP13 and ADAMTS5, while promoting collagen type 2 and aggrecan gene expression. Finally, single-cell RNA sequencing performed on osteoarthritic cartilage explants exposed to Cobimetinib ex vivo confirmed the anti-hypertrophic effect of Cobimetinib on hypertrophy-related gene expression and additionally showed a deletion of chondrocytes with a fibrotic phenotype. This study is a proof of concept that omics data together with a drug repurposing strategy accelerate drug discovery in diseases like osteoarthritis and could quickly lead to many new therapeutic roles for safe and effective drugs.

2026-01-07 | GSE290973 | GEO

RNA-seq of ER+ PDX models treated with GDC-9545

Project description:We measured gene expression using RNA-sequencing for HCI-011 and HCI-003 PDX models with or without treatment of giredestrant (GDC-9545).

2026-03-01 | GSE246365 | GEO

Combined MEKi (GDC-0973) and WNT (G007-LK) treatment in APC and KRAS mutant HCT-15 cell line

Project description:We report RNAseq data from HCT-15 cells were treated wih control(DMSO), GDC-0973, G007-LK and combined GDC-0973 and G007-LK treatmetn for 24 hours.

2019-04-22 | GSE123807 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data